Advanced Filters
noise

Bayside, New York Clinical Trials

A listing of Bayside, New York clinical trials actively recruiting patient volunteers.

Found 1,904 clinical trials
K Kristie Coleman

Non-invasive Vagal Stimulation for Frequent Premature Ventricular Complexes

A prospective sham-controlled randomized clinical trial to assess the effect of low-level tragus stimulation (LLTS) in patients with frequent premature ventricular complexes (PVCs)

18 - 80 years of age All Phase N/A
E Emily R Edwards, PhD

Dialectical Behavior Therapy for Justice-Involved Veterans

Dialectical Behavior Therapy for Justice-Involved Veterans (DBT-J) is a comprehensive, integrative program distinctively designed to address the range of mental health, substance use, case management, and legal needs of Veterans with current or ongoing criminal justice involvement. Data from two prior clinical trials attest to the program's feasibility and acceptability …

18 years of age All Phase N/A

A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to see whether adding liver stereotactic ablative radiotherapy/L-SABR to standard drug therapy is better than standard drug therapy alone for people with metastatic non-small cell lung cancer/NSCLC.

18 years of age All Phase 2

A Study of DF6002 Alone and in Combination With Nivolumab

The purpose of this study is to evaluate the safety, tolerability, drug-levels, drug-effects and preliminary anti-tumor activity of DF6002 alone and in combination with Nivolumab in participants with advanced solid tumors.

18 years of age All Phase 1/2
E Elena Ladas, PhD, RD

A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considering Key Genetic and Sociodemographic Risk Factors

The purpose of this study is determine the effectiveness of a six-month virtually-delivered dietary education intervention (PEDALL) on the prevention of overweight and obesity (OW/OB) during maintenance chemotherapy in children and adolescents with acute lymphoblastic leukemia (ALL).

5 - 21 years of age All Phase N/A
C Carlos M. Reyes-Vidal, MD

Effects of GH and Lirglutide on AgRP

This is a randomized, placebo-controlled, cross-over study with 4 arms. Healthy and GH deficient adults ages 18-45 years will be studied. Arms will consist of 21-day treatment periods and be separated by 8-week washout periods. Subjects will receive, in random order: i) GH alone, ii) GH with liraglutide, iii) liraglutide …

18 - 45 years of age All Phase 4
D Douglas Orr, MD

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug CS5001 in patients with advanced hematological and solid tumors.

18 years of age All Phase 1
C Charu Gandhi

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial

This study is a randomized, open label, multicenter Phase II trial to evaluate the efficacy and safety of botensilimab (a novel Fc enhanced Tree depleting anti-CTLA4) and balstilimab (a novel anti-PD1) relative to ipilimumab and nivolumab in treatment naïve patients with metastatic ccRCC. The study will plan to enroll 120 …

18 years of age All Phase 2
S Stephanie Hyde, CCRP

Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

The hypothesis for this study is that a preparative regimen that maximizes host immunosuppression without myeloablation will be well tolerated and sufficient for engraftment of donor hematopoietic cells. It is also to determine major toxicities from these conditioning regimens, within the first 100 days after transplantation.

- 20 years of age All Phase 1/2

A Study of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS)

GEn1E-1124-002 is a two-part Phase 2 study to evaluate the safety and tolerability of GEn-1124 in subjects with ARDS. Treatment with IV infusion dosing as early as possible after ARDS diagnosis. Subjects will be given a second dose approximately 8 hours after the first dose and will continue with twice …

18 - 80 years of age All Phase 2

Simplify language using AI